Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
about
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesPioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs)Immunogenicity of mAbs in non-human primates during nonclinical safety assessmentSafety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesBridging the gap: facilities and technologies for development of early stage therapeutic mAb candidatesAssessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platformsDevelopmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions.Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.The enhanced pre- and postnatal study for nonhuman primates: update and perspectives.On the emerging role of rabbit as human disease model and the instrumental role of novel transgenic tools.Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.Challenges and approaches for the development of safer immunomodulatory biologics.Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed.The interference of monoclonal antibodies with laboratory diagnosis: clinical and diagnostic implications.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Drug development and nonclinical to clinical translational databases: past and current efforts.Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.A snapshot of biologic drug development: Challenges and opportunities.Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Opportunities to Apply the 3Rs in Safety Assessment Programs.Drug Development of Therapeutic Monoclonal Antibodies.The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations.The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.Research agenda. Guiding limited use of chimpanzees in research.Reviewing the Utility of Two Species in General Toxicology Related to Drug Development.
P2860
Q28079835-6B698EDE-4959-4695-9010-D3CBB37AC134Q28650531-8EC03B95-1FB5-4E5E-B90C-E8642F86E7A4Q30390955-FC0858AD-8E88-4ACB-83E7-9011F34AD9E2Q33895804-57352689-C60B-4BF9-B91B-01D7CA577C2EQ35578028-996723B5-BD4E-4E60-86BD-B9BC1B9B16CCQ35864980-91211367-43D4-4339-88CF-19391CA970EFQ37798387-F62410F6-0018-412A-8995-29CC784FAF09Q37947551-520A6EF3-FF40-419B-8C62-53DB63330030Q37978260-7D6391A5-4A65-4181-94BC-BF265F5F4E3CQ37989800-5EF747F0-C66B-48F0-B14E-4D55EBD0F75FQ37994716-C7E12FCA-AAEE-4DDA-94BA-4261749AF435Q38061448-FF8618B2-8A35-4597-8753-85DAB5344DF0Q38093772-D8A5DEAB-4932-4702-B391-BC26106C2F0DQ38138610-B66D678A-C4E0-4CBF-8E09-0F62AF747354Q38149310-D3083627-58B5-42FE-8B94-B4B92892E4C0Q38208275-B9BE2406-4086-46B7-BC85-141F2291E42EQ38267362-407CEA57-1275-488C-B9BE-1E1A3BD24C6CQ38635412-3C395F65-2849-496C-AE07-5838C32488FCQ38651271-65E4F336-6DED-4BBA-9A7A-339AA26508A6Q38687397-5D0B5984-AF6E-4572-A54C-D8F5E8B72BB3Q38774773-FE0FDD71-47BE-4C98-A905-C139BED541A6Q38876360-22FD4D2C-1FD5-42EA-86D7-792E319382E4Q39558945-CC50413F-A919-4E71-A27D-E723DE3CEA5CQ40216493-14B9B20F-CFE0-41A2-915B-BCF178EFB954Q41551902-99424FF8-9E1F-4FA8-B5FC-97BD2DE7924DQ47428449-8C35E253-7236-4880-BCC4-78AFB98768DAQ50935053-C88B9430-312B-428E-8ECA-C68B4D60DC58Q52837972-5D832F49-36A2-4C7B-B9FE-DF66439E1509Q55090413-F7EC8041-5A80-4A83-A4FD-2C39E3C84FB7
P2860
Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Preclinical development of mon ...... the use of non-human primates
@ast
Preclinical development of mon ...... the use of non-human primates
@en
Preclinical development of mon ...... the use of non-human primates
@nl
type
label
Preclinical development of mon ...... the use of non-human primates
@ast
Preclinical development of mon ...... the use of non-human primates
@en
Preclinical development of mon ...... the use of non-human primates
@nl
prefLabel
Preclinical development of mon ...... the use of non-human primates
@ast
Preclinical development of mon ...... the use of non-human primates
@en
Preclinical development of mon ...... the use of non-human primates
@nl
P2093
P2860
P356
P1476
Preclinical development of mon ...... the use of non-human primates
@en
P2093
Abby Jacobs
Colin Green
Geoff Hale
Kathryn Chapman
Laura Andrews
Lorrene Buckley
Maggie Dempster
Paul Baldrick
P2860
P304
P356
10.4161/MABS.1.5.9676
P407
P577
2009-09-30T00:00:00Z